The relative efficacy and toxicity of E. coli L-asparaginase and epidoxorubicin used in remission induction therapy for childhood acute lymphoblastic leukemia (ALL) were assessed in a randomized trial conducted in Taiwan. All patients had standard-risk ALL, defined as a leukocyte count Ͻ10 × 10 9 /l and were aged between 1 and 2 or 7 and 10 years, or a leukocyte count Ͻ50 × 10 9 /l and were aged between 2 and 7 years, without evidence of a T cell or mature B cell immunophenotype, central nervous system leukemia or expression of two or more myeloid-associated antigens. Ninety-three patients were randomized to receive E. coli L-asparaginase at 10 000 IU/m 2 thrice weekly for nine doses and 108 to receive epidoxorubicin at 20 mg/m 2 weekly for two doses during remission induction with daily prednisolone, weekly vincristine and, on day 22, a dose of etoposide plus cytarabine. Patients treated with L-asparaginase had a significantly higher rate of fatal infection with or without hemorrhage than did those who received epidoxorubicin during remission induction (six of 93 vs none of 108, P = 0.009), resulting in a lower rate of complete remission in the former group (93.6 vs 99.1%, P = 0.05). In addition, patients treated with L-asparaginase had a higher frequency of hyperglycemia and hypoalbuminemia. The overall rate of event-free survival was lower in patients treated with L-asparaginase than in other patients (P = 0.06); estimated 3-year rates were 72% (95% confidence interval, 55-89%) and 87.2% (78-96%), respectively. We conclude that L-asparaginase (Leunase) given at 10 000 IU/m 2 for nine doses was poorly tolerated and resulted in excessive toxicity, both through its effects as a single agent and possibly through potentiation of etoposide.
Introduction
Contemporary treatment programs featuring three or more drugs during remission induction can induce complete remissions in more than 95% of children with acute lymphoblastic leukemia (ALL). For patients with low-or standardrisk ALL, remission induction regimens often contain three drugs and can induce complete remissions in over 98% of patients. Two agents -a glucocorticoid and vincristine -are used in every induction regimen, and most protocols rely on an anthracycline or L-asparaginase as the third agent. 1 In our Taipei Children's Leukemia (TCL) 821 study (1982) (1983) (1984) , in which prednisolone, vincristine and doxorubicin were used for remission induction, all 54 children with standard-risk ALL attained complete remission. 2 In our subsequent TCL 842 study (1984) (1985) (1986) (1987) (1988) , E. coli L-asparaginase (Leunase; Kyowa Hacco Kogyo, Japan) was used as the third agent and administered at 5000 IU/m 2 /day on days 3-10 for eight doses; 115 of 118 children (97%) with standard-risk ALL achieved a complete remission. 3 In the Taiwan Pediatric Oncology Group (TPOG) 882A protocol (1988) (1989) (1990) (1991) (1992) (1993) , L-asparaginase (Leunase) was again used as the third agent at a dosage of 5000 IU/m 2 thrice weekly for nine doses; 208 of 216 children (96.3%) with standard-risk ALL attained a complete remission. 4 Because the relative efficacy as well as the acute and longterm sequelae of an anthracycline and L-asparaginase used for remission induction were uncertain, we initiated a randomized trial -TPOG-ALL-93-SR (standard-risk) protocol (1993-1997) -to address this issue. One group of patients were randomized to receive epidoxorubicin (epirubicin), and the other group L-asparaginase. 5 Although the dosage of E. coli L-asparaginase varied widely between protocols (ie 5000 to 25 000 IU/m 2 ), 4,6-8 we chose the dosage of 10 000 IU/m 2 thrice weekly for nine doses to avoid undertreatment. The unexpectedly high mortality in our patients treated with L-asparaginase prompted us to report our early results.
Patients and methods

Patients
From September 1993 to July 1997, 201 children with newly diagnosed standard-risk ALL in Taiwan were enrolled in the nationwide TPOG-ALL-93-SR protocol. These cases represented 46% of patients in all risk groups treated during the same time period. The protocol was approved by the Human Investigations Committee of each participating hospital and informed consent was obtained from the parents of each patient. The 110 boys and 91 girls ranged in age from 1 to 15 years (median, 3 years and 11 months).
Diagnosis
The diagnosis of ALL was based on the morphologic, cytochemical and immunophenotypic characterization of leukemic blast cells in bone marrow and/or peripheral blood. Bone marrow and peripheral blood smears were stained with a modified version of the Romanowsky method 9 and other standard techniques including periodic acid-Schiff, myeloperoxidase, ASD-chloroacetate esterase and ␣-naphthyl butyrate esterase. Immunophenotypic studies were performed by previously described methods. 10 Standard-risk ALL was defined by the following criteria: (1) leukocyte count /l for patients aged 1 to 2 years or 7 to 10 years; Ͻ50 × 10 9 /l for those aged 2 to 7 years; and (2) non-T, non-B immunophenotype, no central nervous system (CNS) leukemia, as defined by the presence of any leukemic lymphoblasts identified on cytocentrifuged smears of cerebrospinal fluid, 11 or the presence of cranial nerve palsies and the lack of expression of two or more myeloid-associated antigens (CD11, CD13, CD14, CD15 or CD33).
Randomization and treatment
The patients were randomized within each participating institution into two treatment groups (SRL and SRE), which differed only in remission induction therapy. During remission induction, all patients received prednisolone and vincristine; patients in the SRL group were given additional E. coli L-asparaginase (Leunase) at 10 000 IU/m 2 intramuscularly thrice weekly for nine doses, while those in the SRE group were treated with epidoxorubicin 20 mg/m 2 intravenously on days 1 and 8 for two doses (Table 1) . Upon attaining complete remission, all patients received consolidation treatment consisting of six doses of high-dose methotrexate (1 g/m 2 intravenously over 24 h) and daily mercaptopurine over 11 weeks, followed by reinduction treatment with dexamethasone, vincristine, L-asparaginase and epidoxorubicin. Continuation treatment consisted of weekly methotrexate and daily mercaptopurine with pulses of dexamethasone and vincristine every 8 weeks. CNS-directed therapy was based on triple intrathecal treatment with methotrexate, hydrocortisone and cytarabine; cranial irradiation was not given to any patient. There were no significant differences in age, gender or presenting leukocyte count between the two groups ( Table 2) . 
Statistical analysis
Comparisons of the frequencies of mortality, toxicity and complications during remission induction, as well as the complete remission rates between the two study groups, were assessed with Fisher's exact test. Sex distributions were compared with the 2 test, and distributions of age and presenting leukocyte counts with the two-sample t-test. Event-free survival and disease-free survival were estimated by the Kaplan-Meier method and compared with the two-sided log-rank test. Ninety-five percent confidence intervals (CIs) were calculated by Greenwood's formula. Event-free survival (EFS) was analyzed from the start of remission induction, and disease-free survival (DFS) from the time of attaining complete remission to the time of failure. Failures included death or relapse of any kind. In both analyses, cases were censored at the last follow-up date, if no failure was observed. Follow-up data were accrued through August 1997. The impact of the treatment groups, presenting leukocyte count and age on clinical outcome was analyzed by both univariate and multivariate Cox regression models. 
Results
During remission induction, 19 of 93 patients in the SRL groups, compared with eight of 108 in the SRE group, developed a severe infection (P = 0.01, Table 3 ). Five patients in the SRL group died as a result of this complication; one additional patient in this group died of severe infection and upper gastrointestinal tract bleeding during induction therapy. Details of cases with fatal complications are summarized in Table 4 . Hence, altogether, six of 93 patients in the SRL group, as compared with none of the 108 in the SRE group, died during remission induction (P = 0.009). As expected, patients in the SRL group were also more likely than those in the SRE group to have hyperglycemia and hypoalbuminemia (Table  3 ). There were no significant differences in other complications.
Only one patient in the SRE group failed to attain complete remission, while in the SRL group the complete remission rate was significantly lower (93.6 vs 99.1%, P = 0.05) due to the excess number of deaths during this phase of therapy ( Table  5 ). The overall EFS probability was likewise worse in the SRL group (Figure 1 ; P = 0.06). Estimated rates at 3 years post-diagnosis were 72% (55-89% CI), and 87% (78-96%), respectively. The two groups did not differ significantly with respect to DFS (Figure 2 ; P = 0.43). By the Cox regression analysis, treatment group was the only variable with a significant impact on prognosis. Patients treated by the SRL protocol had a 1.56-fold (0.52-4.6 CI) higher risk of failure as compared to those in the SRE group.
Discussion
We attribute the increased frequencies of severe infection and mortality in this study to treatment with L-asparaginase. By depleting asparagine, this agent inhibits protein synthesis, resulting in a variety of metabolic dearrangements and organ dysfunction, including immunosuppression. 12 Since the relative frequencies of febrile neutropenia in this study were not significantly different (Table 3) , we suggest that the primary adverse affect of L-asparaginase was inhibition of normal immune function, including synthesis of immunoglobulin. Additionally, L-asparaginase treatment increases unbound (active) portion of etoposide and its catechol metabolites due to hypoalbuminemia [13] [14] [15] and decreased systemic clearance. 14 The increased concentration of unbound etoposide and its metabolites could be expected to enhance myelosuppression. Indeed, the onset of fatal complications in four patients occurred 1 to 9 days after the etoposide therapy on day 22.
In conventional dosages, L-asparaginase treatment is generally well tolerated and not associated with severe infection. Three forms of the enzyme are available commercially -one derived from Erwinia chrysanthemi, the other prepared from E. coli and the third representing a polyethylene glycol (PEG) form of the E. coli product. The dosages of these three pro-
Figure 1
Event-free survival (EFS) of 201 children with standard-risk ALL. The 3-year EFS in the SRE group was 87 vs 72% in the SRL group.
Figure 2
Disease-free survival (DFS) of 201 children with standard-risk ALL. The 3-year DFS in the SRE group was 89 vs 80% in the SRL group.
ducts are based on their half-lives. PEG-L-asparaginase, which has the longest half-life, is usually administered at 2500 IU/m 2 every other week for two doses in cases of newly diagnosed ALL. By contrast, Erwinia L-asparaginase, with the shortest half-life, is generally given at 10 000 IU/m 2 three times per week for six to 12 doses. In the USA, the dosages of E. coli L-asparaginase (Elspar, Merck Sharp & Dohme, USA) range from 6000 to 10 000 IU/m 2 given two to three times per week for six to 12 doses. In this study, the dosage of L-asparaginase (Leunase) was higher than those used in our two previous studies, because we did not wish to underdose our patients, thus compromising the comparison with epidoxorubicin, and because the dosage was the one recommended by Nesbit and associates, 16 on the basis of results with an E. coli preparation (Crasnitin) produced by Bayer (UK, Germany, Italy, Denmark, Norway).
Why then was the Leunase preparation so poorly tolerated in this study? Until recently, L-asparaginase compounds derived from different strains of E. coli were assumed to have comparable potency. However, recent studies demonstrated that the enzyme activities and half-lives of these products differ substantially. [17] [18] [19] [20] For example, the Crasnitin preparation was found to have a lower enzyme activity and a shorter half-life than other E. coli derivatives. In a German study, the product sold as Medac (Medac, Hamburg, Germany, produced by Kyowa Hacco Kogyo, Japan, and having identical properties to the Leunase product) caused excessive toxicity when given at a dose of 10 000 IU/m 2 at 3 day intervals for eight doses, 21 prompting a 50% reduction in the dosage used in the German frontline ALL and non-Hodgkin lymphoma trials. 18 Thus, in view of the toxicity results encountered in the present study, we elected to reduce the L-asparaginase (Leunase) dosage for the subsequent patients treated in the TPOG-ALL-93-SR by 50%. Since this amendment, L-asparaginase has been administered in reduced dosage to 11 patients, one of whom developed sepsis, but there was no mortality.
This study illustrates the profound adverse impact that can result from a seemingly modest dosage adjustment of a single agent in a multidrug regimen of cancer chemotherapy. Recent studies indicate that substitution of the Erwinia product for E. coli L-asparaginase, without a dosage adjustment for its shorter half-life, can also adversely affect treatment outcome. 22 Together, these findings emphasize that in the design of modern clinical trials of childhood ALL, dosage, administration modalities and schedules of any L-asparaginase products should be very carefully evaluated since products derived from different strains of the same bacteria may display very different biological and clinical effects.
